With increasing incidence of elderly patient population, comorbidities, prolonged ICU stay, invasive therapies, and use of broad-spectrum antibiotics, there is a rising incidence of fungal infection and use of antifungal drugs. Candidemia is the most common invasive fungal infection encountered in the ICU and is the fourth most common cause of bloodstream infection. Candida albicans is the most common identified species, but there is an increasing shift to non-albicans Candida species. Attributable mortality with candidemia could be as high as 47%. Other fungal infections seen in the ICU are invasive aspergillosis and zygomycosis. With increasing threat of developing resistance, antifungal drugs should be used judiciously, either prophylactic, empiric, or as a definitive therapy.